Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.

MLA

Hungria, Vania, et al. “Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.” The New England Journal of Medicine, vol. 391, no. 5, Aug. 2024, pp. 393–407. EBSCOhost, https://doi.org/10.1056/NEJMoa2405090.

APA

Hungria, V., Robak, P., Hus, M., Zherebtsova, V., Ward, C., Ho, P. J., Ribas de Almeida, A. C., Hajek, R., Kim, K., Grosicki, S., Sia, H., Bryant, A., Pitombeira de Lacerda, M., Aparecida Martinez, G., Sureda Balarí, A. M., Sandhu, I., Cerchione, C., Ganly, P., Dimopoulos, M., … Mateos, M.-V. (2024). Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma. The New England Journal of Medicine, 391(5), 393–407. https://doi.org/10.1056/NEJMoa2405090

Chicago

Hungria, Vania, Pawel Robak, Marek Hus, Vera Zherebtsova, Christopher Ward, P Joy Ho, Ana Carolina Ribas de Almeida, et al. 2024. “Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.” The New England Journal of Medicine 391 (5): 393–407. doi:10.1056/NEJMoa2405090.